Viking ($VKTX) has developed a new potent Amylin analog that can lead to up to 10% weight loss in 24 days. The company's focus on obesity treatments, with an emphasis on safety and tolerability, has garnered positive attention from analysts and investors. Viking's management is praised for its strategic approach to pipeline assets, prioritizing the obesity program over NASH. The company's progress in developing cutting-edge drugs has been highlighted in recent presentations, showcasing their expertise and competitive edge in the pharmaceutical industry.
$VKTX Now also has a very potent Amylin Agonists. Upto 10% weight loss in 24 days compared to Vehicle. Poster Presented at ADA 30 minutes ago today. Viking showcasing they have a world class team capable of building best in class drugs. Even Novo & Ely can't seem to come close… https://t.co/vorg3s4XX8
$VKTX 10% loss, another potent weight loss compound in the pipeline https://t.co/lR9H4V1kXS
$VKTX Now also has a very potent Amylin Agonists. Upto 10% weight loss compared to Vehicle. Poster Presented at ADA 30 minutes ago today. Viking showcasing they have a world class team capable of building best in class drugs. Even Novo & Ely can't seem to come close enough… https://t.co/uSbBYft4Wj
$VKTX management exceptionally smart, they know how competitive their pipeline assets are and they are executing well by focusing more on Obesity which is a straightforward program vs NASH at the moment. They can finish both oral and subq phs3 programs on their own Cash is king
$VKTX - when asked today about its Amylin program “it’s pretty interesting- it’s potent. Also can use same oral peptide technology as VK2735 https://t.co/AIXqwFNqPJ
Stick to your convictions. Stock doesn’t go up in a straight line. Price fluctuates all the time. $VKTX is one of top convictions and this is not just recently but from last few years from $3+ However obesity data so far has made my conviction even stronger.
Been saying it for quite some time Tolerability is as important as weight loss numbers $VKTX best in safety https://t.co/yPcxMrLeva
Fact that $VKTX is working on early-stage projects such as this one while aiming to sell their Co suggests... ...that target audience is a Big Pharma that does not already have an #obesity franchise at all. Viking assets would nucleate such a franchise. https://t.co/aGr6k3kPUo
$VKTX great find Jim. 10% weight loss in 24 days. Super potent Amylin analog https://t.co/bpxmovrECC
Nice find @fluffer9 - $VKTX new molecule on Amylin https://t.co/XGn6WkpyGw
$VKTX Amazing - great work from Viking https://t.co/UDASKWRJOk